Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Methotrexate/administration & dosage , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Adrenal Cortex Hormones/administration & dosage , Adult , Chemotherapy, Adjuvant , Drug Therapy, Combination , Humans , Injections, Intralesional , Male , Treatment OutcomeABSTRACT
BACKGROUND: Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events. OBJECTIVE: We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial. METHODS: In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months. RESULTS: Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported. LIMITATIONS: The reduced number of patients could have influenced our results. CONCLUSION: Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.
